Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug

Japan is considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy. The government has pushed generics as a way to lower drug spending but now appears poised to reduce those drug prices further as the economy continues to stall, putting pressure on the national health system, the Kyodo News reports. More from FiercePharmaAsia

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.